FIG. 1.

Multiple Alignment:



FIG. 2.



FIG. 3.



FIG. 4A



293 Transfection

Ni Affinity Chromatography

Imidazole Elution

FIG. 4B



FIG. 5.


NIH 3T3
CCD-1070
OD
1.800
1.600
1.400
1.200
1.000
0.800
0.600
0.400
0.200
0.000
Starve
Mock
30664188
PDGF
Serum
Starve
30664188
bFGF
Serum
Treatments

FIG. 6.


Brdu Proliferation NIH 3T3 5-24
OD
2.000
1.800
1.600
1.400
1.200
1.000
0.800
0.600
0.400
0.200
0.000
serum
starve
mock
30664188 5 ng/ml
30664188 10 ng/ml
30664188 50 ng/ml
30664188 100 ng/ml
30664188 500 ng/ml
Treatments


Cell Number
60000
50000
40000
30000
20000
10000
0
Mock
30664188

FIG. 7.

FIG. 9.


Growth 5-15-00 NHost
Cell Number
140000
120000
100000
80000
60000
40000
20000
0
Mock
10% FBS
30664188
30664188
100ng/ml
HDGF

FIG. 10.

FIG. 10A (without serum)



FIG. 10B (with serum)



FIG. 11.


BrdU Incorporation NIH 3T3
OD
2
1.5
1
0.5
0
serum
starve
mock
3066 10 ng/ml
3066 20 ng/ml
3066 50 ng/ml
3066 100 ng/ml
3066 250 ng/ml
3066 500 ng/ml
3066 1 ug/ml
3066 10 ng/ml
3066 20 ng/ml
3066 50 ng/ml
3066 100 ng/ml
3066 250 ng/ml
3066 500 ng/ml
3066 1 ug/ml
p85
p30
Treatments

FIG. 12

```
                                                        *
hPDGF D     CTPRNYSVNI-REELKLANVVF--FPRCLLVQRCGGNCGCGTVNWRSCTC
mPDGF D     CTPRNHSVNL-REELKLTNAVF--FPRCLLVQRCGGNCGCGTVNWKSCTC
 PDGF C     CTPRNFSVSI-REELKRTDTIF--WPGCLLVKRCGGNCACCLHNCNECQC
 PDGF B     CKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSG---CCNNRNVQCRP
 PDGF A     CKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTG---CCNTSSVKCQP

hPDGF D     NS---GKTVKKYHEVLQFEPGHIKRRGRAKTMALVDIQLDHHERCDC (SEQ ID NO:15)
mPDGF D     SS---GKTVKKYHEVLKFEPGHFKRRGKAKNMALVDIQLDHHERCDC (SEQ ID NO:16)
 PDGF C     VP---SKVTKKYHEVLQLRPKTGVRGLH-KSLTDVA--LEHHEECDC (SEQ ID NO:17)
 PDGF B     TQVQLRPVQVRKIEIVRKKPIF-----KKAT-VT----LEDHLACKC (SEQ ID NO:18)
 PDGF A     SRVHHRSVKVAKVEYVRKKPKL-----KEVQ-VR----LEEHLECAC (SEQ ID NO:19)
```

FIG. 13


Exon 1
Exon 1
Exon 2
Exon 2
Exon 3
Exon 3
Exon 4
Exon 4
Exon 5
Exon 5
Exon 6
Exon 6
Exon 7
Exon 7
(SEQ ID NO:20)
(SEQ ID NO:21)

FIG. 14


A
FBS
—
—
+
200-
116-
98-
66-
55-
36-
30-
21-
14-
6-
p49
p20
1
2
3
B
FBS
DTT
—
—
+
+
—
+
—
+
200
116
98
66
55
36
30
21
14
6
p84
p49
p35
p20
1
2
3
4

FIG. 15


V5 6HIS
A. 27 KDa
GRSYHDRKSKVDLDRL
(SEQ ID NO:22)
GRSYHDRKSKVD.....
(SEQ ID NO:23)
B. 16 KDa
GRSYHDRKSKVDLDRL
(SEQ ID NO:24)
GRSYHDRKSKVD.....
(SEQ ID NO:25)
V5 6HIS
C. 6 Kda
RGRAKTMALVDIQLDHHE
(SEQ ID NO:26)
RGRAKTMALVDIQ.....
(SEQ ID NO:27)

FIG. 16


A
p30
p30/ 4% CS
p85
p85/ 2%CS
p85/ 4%CS
p85/ 8% CS
Calf Serum
B
p30
p30/ 4% FBS
p85
p85/ 2% FBS
p85/ 4% FBS
p85/ 8% FBS
Fetal Bovine Serum

FIG. 17


A
1.2
1
0.8
0.6
0.4
0.2
0
O.D (450 nM)
0
1
10
100
Protein Concentration (ng/ml)
C
80
70
60
50
40
30
20
10
0
Cell Number (X 10⁴)
0
1
2
DAY
B
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
O.D (450 nM)
0
10
1000
Protein Concentration (ng/ml)
D
PDGF BB
PDGF AA
PDGF DD p35
PDGF DD p84
Untreated
IP: Anti-α PDGFR
Blot Anti-PY
IP: Anti-α PDGFR
Blot Anti-α PDGFR
IP: Anti-β PDGFR
Blot Anti-PY
IP: Anti-β PDGFR
Blot Anti-β PDGFR

FIG. 18


Competition of 30664188 p30 or PDGF BB by 30664188 p85
p30
PDGF BB
OD
1.0
0.8
0.6
0.4
0.2
0.0
serum
starve
PDGF BB
p30
p85 50 ng/ml
p85 100 ng/ml
p85 200 ng/ml
p85 500 ng/ml
p85 1000 ng/ml
p85 5000 ng/ml
p85 50 ng/ml
p85 100 ng/ml
p85 200 ng/ml
p85 500 ng/ml
p85 1000 ng/ml
p85 5000 ng/ml
Treatments

FIG. 19

A


PDGF D
PDGF B
PDGF A
gene fragments
21
32
22
124
2
8
19
69
0
2
1
1
302

FIG. 20


CCD1070 Growth: Competition by Anti-Receptor Antiboldies
p30 30664188
PDGF AA
PDGF BB
OD
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
starve
serum
3066
3066 + Rab
3066 + alpha R Ab
3066 + beta R Ab
3066 + alpha & beta R Ab
AA
AA + Rab
AA + alpha R Ab
AA + beta R Ab
AA + alpha & beta R Ab
BB
BB + Rab
BB + alpha R Ab
BB + beta R Ab
BB + alpha & beta R Ab
Treatments

FIG. 21


Smooth Muscle Treated with p30 30664188, PDGF AA, PDGF BB
p35
PDGF AA
PDGF BB
OD
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
serum
starve
3066
3.125 ng/ml
6.25 ng/ml
12.5 ng/ml
25 ng/ml
50 ng/ml
100 ng/ml
AA
3.125 ng/ml
6.25 ng/ml
12.5 ng/ml
25 ng/ml
50 ng/ml
100 ng/ml
BB
3.125 ng/ml
6.25 ng/ml
12.5 ng/ml
25 ng/ml
50 ng/ml
100 ng/ml
Treatments

FIG. 22


Smooth Muscle Cell Proliferation
Cell Number
600000
500000
400000
300000
200000
100000
0
neg control
PDGF
30664188
10% FBS

FIG. 23


Proliferation of Human Saphenous Vein Cells
Cell Number
250000
200000
150000
100000
50000
0
neg control
PDGF
30664188
10% FBS

FIG. 24


Neutralization of 30664188 by Fully Human Polyclonal Ab
30664188-Specific Ab
Control Ab
OD
1.400
1.200
1.000
0.800
0.600
0.400
0.200
0.000
blank
30664188
50 ng/ml
250 ng/ml
500 ng/ml
1 ug/ml
5 ug/ml
50 ng/ml
250 ng/ml
500 ng/ml
1 ug/ml
5 ug/ml
Treatments

Fig. 25.

Panel A



Fig. 25 (cont.)

Panel B



FIG. 26.


BrdU CCD1070 Soluble Alpha PDGFR Competition
OD
1.4
1.2
1
0.8
0.6
0.4
0.2
0
starve
serum
3066
3066 + MOPC21
3066 + sol alpha R
AA
AA + MOPC21
AA + sol alpha R
BB
BB + MOPC21
BB + sol alpha R
Treatments

FIG. 27A



FIG. 27B



FIG. 28


32D Alpha PDGFR Proliferation
2.000
1.500
1.000
0.500
0.000
OD
WEHI
untreated
30661488
PDGF AA
PDGF BB
Treatment

FIG. 29A



FIG. 29B



FIG. 29C



FIG. 29D